AC
REVB icon

Armistice Capital’s Revelation Biosciences REVB Stock Holding History

Armistice Capital’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-323,241
Closed -$388K – 403
2026
Q1 		$388K Buy
323,241
+214,673
+198% +$415K 0.01% 181
2025
Q4 		$347K Buy
108,568
+88,568
+443% +$388K ﹤0.01% 236
2025
Q3 		$114K Buy
+20,000
New +$194K ﹤0.01% 319

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Armistice Capital's REVB Position: Q2 2026 in Review

Armistice Capital sold out of Revelation Biosciences (REVB) in Q2 2026, closing a stake of 323,241 shares — an estimated $388K sold.

Armistice Capital first reported a position in REVB in Q3 2025 and held it in 3 quarters. The position peaked at $388K in Q1 2026. 12 funds tracked by Wall St. Rank hold REVB as of Q2 2026.

  • Armistice Capital reported no remaining Revelation Biosciences position as of Q2 2026 after selling out during the quarter.
  • Armistice Capital sold 323,241 Revelation Biosciences shares in Q2 2026, an estimated $388K.
  • Armistice Capital first reported a position in Revelation Biosciences in Q3 2025 and held it in 3 quarters.
  • Armistice Capital's Revelation Biosciences position peaked at $388K in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.